Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Clinical Characteristics of Patients Requiring a Second Dose of Radioactive Iodine for the Treatment of Graves’ Disease
source: Thyroid
year: 2018
authors: O’Keeffe DT, Abdullah A, Bell M
summary/abstract:Graves’ disease is an autoimmune condition affecting the thyroid gland and is a common cause of hyperthyroidism. The main treatment goals are the reduction in thyroid hormone overproduction either with antithyroid drugs (ATD), surgery or radioactive iodine (RAI) therapy.
The aim of RAI (I-131) therapy is to treat hyperthyroidism by destroying sufficient thyroid tissue to render the patient either euthyroid or hypothyroid. The objective of this work was to examine the outcomes of RAI treatment for Graves’ disease in a large patient cohort over a two year period in a West of Ireland tertiary referral academic medical centre.
In particular, we focused on the characteristics of those patients requiring a second RAI administration. Institutional Review Board approval was obtained for this study and thereafter the clinical records of all the patients who underwent RAI treatment were examined. The data demonstrated that 150 patients underwent RAI treatment from Jan 2014 to Dec 2015.
organization: University Hospital Galway, IrelandDOI: 10.1089/thy.2018.29065.abstracts
read more
Related Content
-
Horizon Therapeutics plc Reports Strong Third-Quarter 2019 ResultsHorizon Therapeutics plc today announced...
-
Update on Graves’ Disease: Advances in Treatment of Mild, Moderate and Severe Thyroid Eye DiseasePurpose of Review: To report the most r...
-
Anna L. Mitchell, MBBS hons, MRes, MRCP, PhDDr. Anna Mitchell is associated as Acade...
-
Living Well With Thyroid Eye Disease – Webinarhttps://www.youtube.com/watch?v=45_mIC7b...
-
Most Patients With Graves’ Disease Treated With Antithyroid Drugs Eventually Require Additional TherapiesGraves’ disease is the most common cau...
-
Eric Hink, MDEric Hink is Associate Professor of opht...
-
Prospectively Recorded and MedDRA-Coded Safety Data of Intravenous Methylprednisolone Therapy in Graves’ Orbit...Context: Safety of intravenous (IV) ste...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.